1 | excess | 4,545 |
2 | diet-induced | 408 |
3 | antecedent | 211 |
4 | surplus | 111 |
5 | interdialytic | 104 |
6 | belly | 86 |
7 | hfd-induced | 67 |
8 | weight/body | 46 |
9 | high-molecular | 29 |
10 | post-cessation | 25 |
11 | dietary-induced | 24 |
12 | low-birth | 21 |
13 | olanzapine-induced | 19 |
14 | weight-to-body | 16 |
15 | overshooting | 15 |
16 | overabundance | 14 |
17 | axle | 12 |
18 | mg/kg/body | 11 |
19 | antipsychotic-associated | 10 |
20 | antipsychotic-related | 10 |
21 | inter-dialytic | 9 |
22 | co2-c | 7 |
23 | nearpoint | 7 |
24 | transplant-associated | 7 |
25 | intake/kg | 6 |
26 | restriction-induced | 6 |
27 | uttara | 6 |
28 | antipsychotics-induced | 5 |
29 | diet-low | 5 |
30 | high-fat-diet-induced | 5 |
31 | immunoadjuvant | 5 |
32 | loperamide-induced | 5 |
33 | month-to-month | 5 |
34 | off-premise | 5 |
35 | emt-like | 4 |
36 | infancy-onset | 4 |
37 | kidney/body | 4 |
38 | liraglutide-induced | 4 |
39 | post-transport | 4 |
40 | rygb-induced | 4 |
41 | sga-induced | 4 |
42 | sibutramine-induced | 4 |
43 | toxicity-associated | 4 |
44 | unstacking | 4 |
45 | appetite-suppressing | 3 |
46 | carbamazepine-induced | 3 |
47 | consumption-induced | 3 |
48 | esa-associated | 3 |
49 | insulin-associated | 3 |
50 | intake-induced | 3 |
51 | inter-hd | 3 |
52 | prerevision | 3 |
53 | raya | 3 |
54 | septum-to-body | 3 |
55 | unautoprocessed | 3 |
56 | 0.25ml | 2 |
57 | 14-y | 2 |
58 | 150-mg/kg-body | 2 |
59 | 221,000 | 2 |
60 | 274,000 | 2 |
61 | 8775 | 2 |
62 | co-feeding | 2 |
63 | cofactor-dependent | 2 |
64 | disease-inducing | 2 |
65 | mass-to-body | 2 |
66 | mm/gps/kg | 2 |
67 | olz-induced | 2 |
68 | uvb-sensitized | 2 |
69 | weight/birth | 2 |
70 | 'exploratory | 1 |
71 | 0.1ml/10g | 1 |
72 | 0.8-lb | 1 |
73 | 1.5kg | 1 |
74 | 11.8-kg | 1 |
75 | 145/kg | 1 |
76 | 19ca | 1 |
77 | 280,958 | 1 |
78 | 5.7±0.90kg | 1 |
79 | age/birth | 1 |
80 | alport-like | 1 |
81 | annormal | 1 |
82 | asthenic-neurotic | 1 |
83 | cessation-induced | 1 |
84 | chlf-induced | 1 |
85 | compound/dried | 1 |
86 | crp/phospholipid | 1 |
87 | diet-on | 1 |
88 | diet/streptozotocin-induced | 1 |
89 | easy-fix | 1 |
90 | fhht-like | 1 |
91 | fosfomycin/kgbody | 1 |
92 | hypomaniac | 1 |
93 | ige/body | 1 |
94 | intake/body | 1 |
95 | mg/kgbody | 1 |
96 | mortality/chd | 1 |
97 | pad-body | 1 |
98 | pad-derived | 1 |
99 | pads/body | 1 |
100 | protein/lower | 1 |
101 | rate-determined | 1 |
102 | receptor-/human | 1 |
103 | restriction-based | 1 |
104 | samut | 1 |
105 | size/birth | 1 |
106 | transfer-fluorescence | 1 |
107 | weight-body | 1 |
108 | wet-bale | 1 |
1 | 'exploratory | 1 |
2 | 0.1ml/10g | 1 |
3 | 0.25ml | 2 |
4 | 0.8-lb | 1 |
5 | 1.5kg | 1 |
6 | 11.8-kg | 1 |
7 | 14-y | 2 |
8 | 145/kg | 1 |
9 | 150-mg/kg-body | 2 |
10 | 19ca | 1 |
11 | 221,000 | 2 |
12 | 274,000 | 2 |
13 | 280,958 | 1 |
14 | 5.7±0.90kg | 1 |
15 | 8775 | 2 |
16 | age/birth | 1 |
17 | alport-like | 1 |
18 | annormal | 1 |
19 | antecedent | 211 |
20 | antipsychotic-associated | 10 |
21 | antipsychotic-related | 10 |
22 | antipsychotics-induced | 5 |
23 | appetite-suppressing | 3 |
24 | asthenic-neurotic | 1 |
25 | axle | 12 |
26 | belly | 86 |
27 | carbamazepine-induced | 3 |
28 | cessation-induced | 1 |
29 | chlf-induced | 1 |
30 | co-feeding | 2 |
31 | co2-c | 7 |
32 | cofactor-dependent | 2 |
33 | compound/dried | 1 |
34 | consumption-induced | 3 |
35 | crp/phospholipid | 1 |
36 | diet-induced | 408 |
37 | diet-low | 5 |
38 | diet-on | 1 |
39 | diet/streptozotocin-induced | 1 |
40 | dietary-induced | 24 |
41 | disease-inducing | 2 |
42 | easy-fix | 1 |
43 | emt-like | 4 |
44 | esa-associated | 3 |
45 | excess | 4,545 |
46 | fhht-like | 1 |
47 | fosfomycin/kgbody | 1 |
48 | hfd-induced | 67 |
49 | high-fat-diet-induced | 5 |
50 | high-molecular | 29 |
51 | hypomaniac | 1 |
52 | ige/body | 1 |
53 | immunoadjuvant | 5 |
54 | infancy-onset | 4 |
55 | insulin-associated | 3 |
56 | intake-induced | 3 |
57 | intake/body | 1 |
58 | intake/kg | 6 |
59 | inter-dialytic | 9 |
60 | inter-hd | 3 |
61 | interdialytic | 104 |
62 | kidney/body | 4 |
63 | liraglutide-induced | 4 |
64 | loperamide-induced | 5 |
65 | low-birth | 21 |
66 | mass-to-body | 2 |
67 | mg/kg/body | 11 |
68 | mg/kgbody | 1 |
69 | mm/gps/kg | 2 |
70 | month-to-month | 5 |
71 | mortality/chd | 1 |
72 | nearpoint | 7 |
73 | off-premise | 5 |
74 | olanzapine-induced | 19 |
75 | olz-induced | 2 |
76 | overabundance | 14 |
77 | overshooting | 15 |
78 | pad-body | 1 |
79 | pad-derived | 1 |
80 | pads/body | 1 |
81 | post-cessation | 25 |
82 | post-transport | 4 |
83 | prerevision | 3 |
84 | protein/lower | 1 |
85 | rate-determined | 1 |
86 | raya | 3 |
87 | receptor-/human | 1 |
88 | restriction-based | 1 |
89 | restriction-induced | 6 |
90 | rygb-induced | 4 |
91 | samut | 1 |
92 | septum-to-body | 3 |
93 | sga-induced | 4 |
94 | sibutramine-induced | 4 |
95 | size/birth | 1 |
96 | surplus | 111 |
97 | toxicity-associated | 4 |
98 | transfer-fluorescence | 1 |
99 | transplant-associated | 7 |
100 | unautoprocessed | 3 |
101 | unstacking | 4 |
102 | uttara | 6 |
103 | uvb-sensitized | 2 |
104 | weight-body | 1 |
105 | weight-to-body | 16 |
106 | weight/birth | 2 |
107 | weight/body | 46 |
108 | wet-bale | 1 |
1 | 221,000 | 2 |
2 | 274,000 | 2 |
3 | 8775 | 2 |
4 | 280,958 | 1 |
5 | 19ca | 1 |
6 | uttara | 6 |
7 | raya | 3 |
8 | 0.8-lb | 1 |
9 | co2-c | 7 |
10 | hypomaniac | 1 |
11 | asthenic-neurotic | 1 |
12 | inter-dialytic | 9 |
13 | interdialytic | 104 |
14 | sga-induced | 4 |
15 | rygb-induced | 4 |
16 | hfd-induced | 67 |
17 | loperamide-induced | 5 |
18 | liraglutide-induced | 4 |
19 | intake-induced | 3 |
20 | sibutramine-induced | 4 |
21 | olanzapine-induced | 19 |
22 | carbamazepine-induced | 3 |
23 | chlf-induced | 1 |
24 | diet/streptozotocin-induced | 1 |
25 | cessation-induced | 1 |
26 | restriction-induced | 6 |
27 | consumption-induced | 3 |
28 | antipsychotics-induced | 5 |
29 | diet-induced | 408 |
30 | high-fat-diet-induced | 5 |
31 | dietary-induced | 24 |
32 | olz-induced | 2 |
33 | compound/dried | 1 |
34 | rate-determined | 1 |
35 | restriction-based | 1 |
36 | unautoprocessed | 3 |
37 | esa-associated | 3 |
38 | antipsychotic-associated | 10 |
39 | insulin-associated | 3 |
40 | transplant-associated | 7 |
41 | toxicity-associated | 4 |
42 | antipsychotic-related | 10 |
43 | pad-derived | 1 |
44 | uvb-sensitized | 2 |
45 | inter-hd | 3 |
46 | mortality/chd | 1 |
47 | crp/phospholipid | 1 |
48 | overabundance | 14 |
49 | transfer-fluorescence | 1 |
50 | fhht-like | 1 |
51 | emt-like | 4 |
52 | alport-like | 1 |
53 | wet-bale | 1 |
54 | axle | 12 |
55 | off-premise | 5 |
56 | 0.1ml/10g | 1 |
57 | 11.8-kg | 1 |
58 | 145/kg | 1 |
59 | intake/kg | 6 |
60 | mm/gps/kg | 2 |
61 | 5.7±0.90kg | 1 |
62 | 1.5kg | 1 |
63 | disease-inducing | 2 |
64 | co-feeding | 2 |
65 | unstacking | 4 |
66 | appetite-suppressing | 3 |
67 | overshooting | 15 |
68 | month-to-month | 5 |
69 | low-birth | 21 |
70 | age/birth | 1 |
71 | size/birth | 1 |
72 | weight/birth | 2 |
73 | annormal | 1 |
74 | 0.25ml | 2 |
75 | receptor-/human | 1 |
76 | diet-on | 1 |
77 | prerevision | 3 |
78 | post-cessation | 25 |
79 | high-molecular | 29 |
80 | protein/lower | 1 |
81 | excess | 4,545 |
82 | surplus | 111 |
83 | infancy-onset | 4 |
84 | immunoadjuvant | 5 |
85 | antecedent | 211 |
86 | cofactor-dependent | 2 |
87 | nearpoint | 7 |
88 | post-transport | 4 |
89 | samut | 1 |
90 | diet-low | 5 |
91 | easy-fix | 1 |
92 | 14-y | 2 |
93 | pad-body | 1 |
94 | 150-mg/kg-body | 2 |
95 | septum-to-body | 3 |
96 | mass-to-body | 2 |
97 | weight-to-body | 16 |
98 | weight-body | 1 |
99 | ige/body | 1 |
100 | intake/body | 1 |
101 | mg/kg/body | 11 |
102 | pads/body | 1 |
103 | weight/body | 46 |
104 | kidney/body | 4 |
105 | mg/kgbody | 1 |
106 | fosfomycin/kgbody | 1 |
107 | belly | 86 |
108 | 'exploratory | 1 |